Lam CSP, Giczewska A, Sliwa K, et al. - This study was undertaken to investigate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index heart failure hospitalization (HFH) in the Vericiguat Global Study in individuals with heart failure with reduced ejection fraction trial. Mean age was 67 years, 24% were women, 64% were White, 22% were Asian, and 5% were Black among 5,050 patients in the VICTORIA trial. The primary endpoint included time to a composite of HFH or cardiovascular death. Time to HFH, cardiovascular death, a composite of all-cause mortality or HFH, all-cause death, and total HFH were considered as secondary endpoints. The findings revealed that among patients with worsening chronic HF, those in closest proximity to their index HFH had the highest risk of cardiovascular death or HFH, irrespective of age or clinical risk factors. The results showed that the advantage of vericiguat did not differ significantly across the spectrum of risk in worsening heart failure.